1. Liu, Lu, Feng, Xikang, Li, Haimei, Qian, Qiujin, Wang, Yufeng. . Deep learning model reveals potential risk genes for ADHD, especially Ephrin receptor gene EPHA5. In Briefings in bioinformatics, 22, . doi:10.1093/bib/bbab207. https://pubmed.ncbi.nlm.nih.gov/34109382/
2. Chen, Zhiming, Chen, Ji, Ren, Dandan, Mao, Beibei, Ma, Haitao. 2020. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. In Aging, 13, 598-618. doi:10.18632/aging.202169. https://pubmed.ncbi.nlm.nih.gov/33288738/
3. Li, Shibao, Zhu, Yingfeng, Ma, Chunguang, Li, Xiangyu, Guan, Ming. 2015. Downregulation of EphA5 by promoter methylation in human prostate cancer. In BMC cancer, 15, 18. doi:10.1186/s12885-015-1025-3. https://pubmed.ncbi.nlm.nih.gov/25609195/
4. Wu, Youjia, Song, Honghua, Sun, Baolan, Xu, Meiyu, Shi, Jinlong. 2015. DNA Methylation of the EphA5 Promoter Is Associated with Rat Congenital Hypothyroidism. In Journal of molecular neuroscience : MN, 57, 203-10. doi:10.1007/s12031-015-0603-9. https://pubmed.ncbi.nlm.nih.gov/26109526/
5. Han, Xu, Liu, Tianyu, Zhai, Jiabao, Zhou, Haibo, Tian, Wenjing. 2022. Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer. In PeerJ, 10, e13774. doi:10.7717/peerj.13774. https://pubmed.ncbi.nlm.nih.gov/36164608/
6. Huang, Weimei, Lin, Anqi, Luo, Peng, Guo, Linlang, Zhang, Jian. 2020. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. In Cancer gene therapy, 28, 864-874. doi:10.1038/s41417-020-0207-6. https://pubmed.ncbi.nlm.nih.gov/32759987/
7. Zhang, Chengcheng, He, Yiwei, Liu, Lu. 2024. Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization. In The journal of headache and pain, 25, 100. doi:10.1186/s10194-024-01805-3. https://pubmed.ncbi.nlm.nih.gov/38867170/
8. Zhang, Jingwen, Zhang, Zhihao, Song, Weiwei, Liu, Jumin. 2020. EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion. In Molecular and cellular probes, 52, 101566. doi:10.1016/j.mcp.2020.101566. https://pubmed.ncbi.nlm.nih.gov/32234341/
9. Li, Yongfei, Chu, Jiahui, Feng, Wanting, Huang, Yi, Yin, Yongmei. 2019. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33, 4851-4865. doi:10.1096/fj.201701561RRRR. https://pubmed.ncbi.nlm.nih.gov/30620624/
智鼠故事 
